Key facts, as of
As of October 8, 2026, Incyte Corporation (INCY) trades at $113.44, up 30.1% over the past year. Its 52-week range runs from $82.82 to $132.60; the price is 14.4% below that high. It is 25.9% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +28.7%, against +312.9% for the S&P 500 (SPY). It sits 5.9% above its 200-day average of $107.10, the usual sign of a long-term uptrend. Its 30-day volatility is 24.2% annualized, which we rate medium risk. It has a trailing P/E of 14.5.
Cite: Portfolio Terminal, "Incyte Corporation (INCY) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/incy
Where it trades today
trading 62% of the way up its 52-week range
How the price has moved
How far it is from its record
Incyte Corporation (INCY) is 25.9% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +28.7%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- INCY trades at 14.5x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- INCY carries a beta of 0.74, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- INCY remains in a bearish short-term trend and sits 14.4% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- INCY is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for INCY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for INCY. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Incyte Corporation does
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784…
What analysts expect
INCY carries a buy consensus from 24 analysts, with an average price target of $128.92 versus $113.44 today (+13.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
INCY generated $5.82B in trailing revenue (37.7% year over year), with a 27.7% net margin, and $1.18B of free cash flow, supported by $4.50B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $5.14B | $4.77B | $1.34B | $1.29B | $6.59 | $1.33B |
| 2024 | $4.24B | $3.93B | $101.29M | $32.62M | $0.16 | $235.17M |
| 2023 | $3.70B | $3.44B | $655.36M | $597.60M | $2.67 | $449.00M |
| 2022 | $3.39B | $3.19B | $591.63M | $340.66M | $1.53 | $892.11M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
INCY is in 5 of the 30 ETFs we track. It weighs most in XLV: 0.34% of the fund, holding #46 of 62.
Famous investors who hold it
INCY is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.55% of the portfolio, position #26 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
INCY beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 7.8% below its 50-day average and 5.9% above its 200-day.
- RSI at 32 is neither stretched nor washed out.
- The nearest ceiling is $119.51 (+5.4%), the nearest floor $109.31 (-3.6%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is INCY a good investment in 2026?
Incyte Corporation trades at a P/E ratio of 14.5, with medium volatility (24.2% annualized). Recent trend shows weakness.
What is the risk level of INCY?
Based on 30-day volatility of 24.2%, INCY has MEDIUM risk. Beta of 0.74 indicates lower sensitivity to market movements than average.
Does INCY pay dividends?
Incyte Corporation currently does not pay a regular dividend.
How far is INCY from its all-time high?
Incyte Corporation is 25.9% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +28.7%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold INCY?
5 of the 30 popular ETFs we track hold Incyte Corporation. The largest weights: XLV (0.34%), SPY (0.03%), IVV (0.03%), VOO (0.03%) and VTI (0.03%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is INCY?
0.03%, as of August 31, 2026: INCY is holding #385 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.31 in Incyte Corporation.
Which famous investors own INCY?
Renaissance Technologies (0.55% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for INCY?
The average analyst price target for Incyte Corporation (INCY) is $128.92 based on 24 analyst estimates, about 13.6% above the current price of $113.44. The published range runs from $86.00 to $157.00.
How much revenue does INCY generate?
Incyte Corporation reported $5.82B in trailing twelve-month revenue. Revenue growth is running at 37.7% year over year. Net margin sits at 27.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare INCY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.